Skip to main content

An illustration picture shows blister-packs and a box of acne drug Diane-35, which is also used as a contraceptive, in a pharmacy in Andernos, France, Jan. 30, 2013.

REGIS DUVIGNAU/REUTERS

Health Canada says it will conduct a review of all available safety information about a controversial acne medication that is often prescribed to young women as birth control.

The move comes after France temporarily banned the prescription of Diane-35 and following media reports that the drug may have played a role in the deaths of 11 young women in Canada.

But Health Canada said in a statement late Thursday that it will not take any action until the review is complete.

Story continues below advertisement

Diane-35 has a long, tortuous history but nevertheless remains a popular product, especially with teenage girls concerned about acne.

The drug is supposed to be prescribed only as a treatment of last resort for young women with severe acne. But it is often prescribed off-label as an oral contraceptive.

Diane-35 is even packaged like birth-control pills, in a 28-pill holder and taken to coincide with a woman's menstrual cycle, ostensibly because in young women acne breakouts are often related to menstrual cycles.

Most birth-control pills help clear up acne because they stabilize hormone levels.

One of the ingredients in Diane-35, cyproterone acetate, is seen as particularly potent. However, it is more likely to cause blood clots, which is why the drug should not be used as an oral contraceptive.

Earlier this week, the Toronto Star reported that there were 195 reports of severe adverse effects among users of Diane-35. That number included 11 women who died, among them four teenagers.

Diane-35 was introduced into Canada in the 1990s with a flashy billboard advertising campaign in which it was touted as "The Acne Solution." The manufacturer, Berlex Canada, clashed with regulators about the legality of those ads. (Berlex was taken over by Bayer Inc., which sells the drug in Canada.)

Story continues below advertisement

Over the years, Health Canada has issued repeated warnings about Diane-35.

Bayer said in a statement Thursday that the product is safe when used properly and it was "not aware of any new scientific evidence leading to a change in the positive benefit-risk assessment of Diane-35."

Europe's drug regulator, the European Medicines Agency (EMA), issued a statement late on Wednesday saying France had indicated its intention to ask for a European-led safety review of the medicine, but had not yet done so.

It said once France made a formal request, its risk-assessment committee would "evaluate all evidence on the benefits and risks of these medicines and give a recommendation on whether their marketing authorizations should be varied, suspended or revoked."

With a report from Reuters

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies